RecruitingPhase 1NCT06436742
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
Studying Congenital myasthenic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Intervention
- ARGX-119(biological)
- Enrollment
- 16 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (9)
- UC Davis Medical Center, Sacramento, California, United States
- Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
- Ottawa Hospital Research Institute - Civic Campus, Ottawa, Canada
- CHU - Hospital de la Timone, Marseille, France
- Group Hospitalier Pitie-Salpetriere, Paris, France
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
- Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur), Valencia, Spain
- Clinical Trials Centre - South Eastern Health and Social Care Trust - The Ulster Hospital, Belfast, United Kingdom
- John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06436742 on ClinicalTrials.govOther trials for Congenital myasthenic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06630650A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic SyndromesNational Institute of Neurological Disorders and Stroke (NINDS)
- RECRUITINGPHASE1NCT07226726Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome SolutionThe Foundation for Orthopaedics and Regenerative Medicine
- RECRUITINGNCT06078553A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4argenx